Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drug Label Rule Is “In Its Final Stages,” Crawford Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting Commissioner Crawford has given FDA staff “one more week” to work out final language of the revised drug labeling format rule.

You may also be interested in...

Labeling Rule Could Strike Implied Indications, GSK Exec Says

The "Highlights" section of the revised labeling will be the biggest challenge due to its size restriction, GSK Strategic Product Labeling Group Director Hardy says. She recommends that firms prepare to rework their labels but cautioned against investing a lot of time anticipating a rule change that might not happen.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts